Theriva™ biologics announces fast track designation granted by the u.s. fda for vcn-01 for the treatment of metastatic pancreatic cancer

Rockville, md., may 23, 2024 (globe newswire) -- theriva™ biologics (nyse american: tovx), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that the u.s. food and drug administration (fda) has granted fast track designation (ftd) to lead clinical candidate vcn-01 in combination with gemcitabine and nab-paclitaxel to improve progression-free survival and overall survival in patients with metastatic pancreatic adenocarcinoma. in virage, the ongoing multinational phase 2b clinical study, intravenous vcn-01 is being evaluated in combination with standard-of-care (soc) chemotherapy (gemcitabine/nab-paclitaxel) as a first line therapy for patients with pancreatic ductal adenocarcinoma (pdac). previously, the fda granted orphan drug designation to vcn-01 for treatment of pdac.
TOVX Ratings Summary
TOVX Quant Ranking